Piper Sandler Reiterates Overweight on Alkermes, Lowers Price Target to $37

Benzinga · 10/25 14:55
Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $38 to $37.